A Biomarker of Inflammation, Fibrosis, Cardiovascular Diseases, Metabolic Syndrome and Tumor |
|
Using galectin-3 to reduce heart failure rehospitalization
|
Increasing attention is being paid towards reducing short-term heart failure readmissions in recent years. Biomarkers such as galectin-3 are likely to play pivotal roles in future heart failure management strategies as they can provide objective information on various pathophysiologic processes involved in heart failure. Galectin-3 is a biomarker of inflammation and fibrosis, which is strongly associated with adverse remodeling of the myocardium and subsequent left ventricular dysfunction. Clinically, elevated galectin-3 levels are associated with increased risk for short- and long-term risk for mortality and heart failure readmission. Galectin-3 can provide incremental predictive value for adverse events over natriuretic peptides. Although significant work is still required to further define the role of galectin-3, it has the potential to become an important part of future heart failure management algorithms by helping to provide an individualized risk profile, which can be used to optimize resource allocation and improve treatment outcomes. |
Xue, Y, et al. Future Cardiol. 2014 Mar;10(2):221-7. doi: 10.2217/fca.14.9. |
Adiponectin downregulates galectin-3 whose cellular form is elevated whereas its soluble form is reduced in type 2 diabetic monocytes |
Galectin-3 plays a role in atherosclerotic diseases, and the effect of adiponectin that protects from atherosclerotic diseases on monocytic galectin-3 was analysed. Adiponectin reduced galectin-3 mRNA, its cellular and soluble form, and this effect was impaired in T2D cells. Cellular galectin-3 was higher in monocytes of overweight than normal-weight donors and was highest in T2D cells. Cellular galectin-3 positively correlated with the BMI of the donors and negatively with soluble monocyte galectin-3. Circulating levels of total adiponectin did not correlate with cellular or soluble galectin-3 indicating that additional factors contribute to higher cellular monocytic galectin-3 in obesity and T2D. |
Weber M, et al. FEBS Lett. 2009 Nov 19;583(22):3718-24. Epub 2009 Oct 8. |
|
|
|
|
|
 |
Code No.: SK00199-01
Size: 96 T
Price: $360.00 USD
Standard Range:156-10000 pg/ml
Sensitivity: 10 pg/ml
Sample Type: serum, plasma
Sample Volume: 100 uL of diluted samples
Dilution Factor:
Intra CV: 4-6%
Inter CV: 8-10%
Protocol: PDF |
|
Code No.: SK00199-05
Size: 96 T
Price: $560.00 USD
Standard Range:3.12-200 pg/ml
Sensitivity: 1 pg/ml
Sample Type: serum, plasma
Sample Volume: 100 uL of diluted samples
Dilution Factor:
Intra CV: 4-6%
Inter CV: 8-10%
Protocol:PDF
|
|
Mouse Galectin-3 ELISA
Code No.: SK00199-03
Size: 96 T
Price: $420.00 USD
Standard Range:15.6-1000 pg/ml
Sensitivity: 7.8pg/ml
Sample Type: serum, plasma
Sample Volume: 100 uL of diluted samples
Dilution Factor:
Intra CV: 4-6%
Inter CV: 8-10%
Protocol: PDF |
|
Code No.: 00199-03-100
Size: 100 ug
Price: $360.00 USD
|
|
Code No.: A00199-01-100
Size: 100 ug
Price: $220.00 USD
Host: Rabbit
Immunogen: Human Galectin-3 rec.
AntibodyType:IgG
Purification: Protein A affinity
Applications: IHC, E
I
Protocol: PDF |
|
|
|
|
Name |
Code No. |
Size |
Price |
ELISA |
|
|
|
Galectin-3 (Human) ELISA Kit |
SK00199-01 |
96 T |
360.00 |
Galectin-3 (Human) ELISA Kit |
SK00199-01B |
192 T |
684.00 |
Galectin-3 (Human) ELISA Kit |
SK00199-01C |
384 T |
1152.00 |
Galectin-3 (Human) ELISA Kit |
SK00199-01T |
960 T |
2520.00 |
Galectin-3 (Human) ELISA Kit |
SK00199-01G |
1920 T |
4290.00 |
Galectin-3 (Human) Ultrasenstive ELISA Kit |
SK00199-05 |
96 T |
560.00 |
Galectin-3 (Human) ELISA Kit |
SK00199-02 |
96 T |
420.00 |
Galectin-3 ( Mouse) ELISA Kit |
|
96 T |
420.00 |
Recombinant |
|
|
|
Galectin (Human) , Rec. |
|
100 ug |
360.00 |
Galectin (Mouse) , Rec. |
|
100 ug |
360.00 |
Antibody |
|
|
|
Rabbit Anti galectin-3 (Human) IgG |
|
100 ug |
220.00 |
Mouse anti galectin-3 (Human) Polyclonal IgG |
|
50 ug |
360.00 |
Anti galectin-3 (Human) Monoclonal IgG |
|
100 ug |
260.00 |
Anti galectin-3 (Human) Monoclonal IgG |
|
500 ug |
590.00 |
Anti galectin-3 (Human) Monoclonal IgG |
|
100 ug |
260.00 |
Anti galectin-3 (Human) Monoclonal IgG |
|
500 ug |
590.00 |
Anti galectin-3 (Human) Monoclonal IgG |
|
100 ug |
260.00 |
Anti galectin-3 (Human) Monoclonal IgG |
|
500 ug |
590.00 |
Anti galectin-3 (Human) Monoclonal IgG |
|
100 ug |
260.00 |
Anti galectin-3 (Human) Monoclonal IgG |
|
500 ug |
590.00 |
Anti galectin-3 (Human) Monoclonal IgG |
|
100 ug |
260.00 |
Anti galectin-3 (Human) Monoclonal IgG |
|
500 ug |
590.00 |
Anti galectin-3 (Human) Monoclonal IgG |
|
100 ug |
260.00 |
Anti galectin-3 (Human) Monoclonal IgG |
|
500 ug |
590.00 |
|
1: Wiwanitkit V. Galectin 3 in heart failure. Clin Res Cardiol. 2010 Apr 7. [Epubahead of print]
2: Chiu CG, ET AL. Diagnostic Utility of Galectin-3 in Thyroid Cancer. Am J Pathol. 2010 Apr 2. [Epub ahead of print]
3: Sakaki M, ET AL. Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest. 2010 Feb;57(1-2):152-7.
4: Christenson RH, ET AL. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. Clin Biochem. 2010 May;43(7-8):683-90. Epub 2010 Feb 11.
|
|
|
|
|
|